U.S. Naltrexone And Buprenorphine Market Size & Outlook
U.S. naltrexone and buprenorphine market, 2018-2030 (US$M)
Related Markets
U.S. naltrexone and buprenorphine market highlights
- The U.S. naltrexone and buprenorphine market generated a revenue of USD 1,253.6 million in 2023 and is expected to reach USD 2,972.1 million by 2030.
- The U.S. market is expected to grow at a CAGR of 13.1% from 2024 to 2030.
- In terms of segment, naltrexone was the largest revenue generating product in 2023.
- Naltrexone is the most lucrative product segment registering the fastest growth during the forecast period.
Naltrexone and buprenorphine market data book summary
| Market revenue in 2023 | USD 1,253.6 million |
| Market revenue in 2030 | USD 2,972.1 million |
| Growth rate | 13.1% (CAGR from 2023 to 2030) |
| Largest segment | Naltrexone |
| Fastest growing segment | Naltrexone |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Buprenorphine, Naltrexone |
| Key market players worldwide | Indivior PLC Ordinary Share, Collegium Pharmaceutical Inc, Alkermes PLC, Orexo AB, Titan Pharmaceuticals Inc, Omeros Corp, Camurus AB, Sun Pharmaceutical Industries |
Other key industry trends
- In terms of revenue, U.S. accounted for 35.2% of the global naltrexone and buprenorphine market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. naltrexone and buprenorphine market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 2,972.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Naltrexone and Buprenorphine Market Scope
Naltrexone and Buprenorphine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. naltrexone and buprenorphine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to naltrexone and buprenorphine market will help companies and investors design strategic landscapes.
Naltrexone was the largest segment with a revenue share of 70.05% in 2023. Horizon Databook has segmented the U.S. naltrexone and buprenorphine market based on buprenorphine, naltrexone covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to U.S. naltrexone and buprenorphine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. naltrexone and buprenorphine market databook
-
Our clientele includes a mix of naltrexone and buprenorphine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. naltrexone and buprenorphine market , including forecasts for subscribers. This country databook contains high-level insights into U.S. naltrexone and buprenorphine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. naltrexone and buprenorphine market size, by product, 2018-2030 (US$M)
U.S. Naltrexone and Buprenorphine Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
